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Abstract
Rationale Impulsivity is associated with a number of
psychiatric disorders, most notably attention deficit/
hyperactivity disorder (ADHD). Drugs that augment
catecholamine function (e.g. methylphenidate and the
selective noradrenaline reuptake inhibitor atomoxetine)
have clinical efficacy in ADHD, but their precise
mechanism of action is unclear.
Objective The objective of this study is to investigate the
relative contribution of dopamine (DA) and noradrenaline
(NA) to the therapeutic effects of clinically effective drugs
in ADHD using rats selected for high impulsivity on the
five-choice serial reaction time task (5CSRTT).
Methods We examined the effects of direct and indirect DA
and NA receptor agonists and selective DA and NA
reuptake inhibitors in rats showing high and low levels of
impulsivity on the 5CSRTT (designated high impulsive
‘HI’ and low impulsive ‘LI’, respectively). Drugs were
administered by systemic injection in a randomized,
counterbalanced manner.
Results Low doses of quinpirole (a D2/D3 agonist) and
sumanirole (a D2 agonist) selectively reduced impulsivity
on the 5CSRTT, whilst higher doses resulted in increased
omissions and slower response latencies. The NA reuptake
inhibitor, atomoxetine, and the alpha-2 adrenoreceptor ago-
nist, guanfacine, dose dependently decreased premature
responding. The dopaminergic reuptake inhibitor GBR-
12909 increased impulsivity, whereas the nonselective DA
andNAreuptakeinhibitormethylphenidatehadnosignificant
effect on impulsive responses in HI and LI rats.
Conclusions These findings indicate that highimpulsivitycan
be ameliorated in rats by drugs that mimic the effects of DA
andNA,justasinADHD,andthatactivationofD2/3receptors
selectively decreases high impulsivity on the 5CSRTT.
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Introduction
Impulsivity encompasses a wide variety of behavioural
phenomena, often described as a predisposition towards
rapid, unplanned responses to internal or external stimuli
with a diminished regard for their negative consequences
(Moeller et al. 2001; Chamberlain and Sahakian 2007;
Potenza 2007). In its pathological form, impulsivity
represents one of three main symptoms of attention deficit/
hyperactivity disorder [ADHD; DSM-IV-TR, American Psy-
chiatric Association (Newcorn et al. 2001; Solanto 2002)].
Treatment of ADHD relies on typical psychostimulant drugs,
notably amphetamine and methylphenidate, which act to
increase both noradrenergic and dopaminergic activity in the
brain by blocking the noradrenaline (NA) and dopamine
(DA) transporters (Elia et al. 1999; Kutcher et al. 2004;
Solanto 2002; McKittrick and Abercrombie 2007). However,
despite their clinical efficacy, the precise mechanism of
action of these treatments is poorly understood.
Clues to the aetiology of ADHD have mainly emerged
from brain imaging studies in affected individuals, which
strongly implicate brain DA dysfunction. For example, PET
studies demonstrate impaired presynaptic DA function in
the prefrontal cortex (PFC, Ernst et al. 1998), dysfunction
of the dopamine transporter (DAT, Dougherty et al. 1999;
Krause et al. 2000), and decreased DA D2/ D3 receptor
availability (Volkow et al. 2009). Further insights have
emerged from animal models of impulsivity (Fernando and
Robbins 2011), for example in rats exhibiting high
impulsive behaviour assessed using the five-choice serial
reaction time task (5CSRTT), which show a reduced
density of DA D2/D3 receptors in the ventral striatum
(Dalley et al. 2007). However, the relative involvement of
DA D2 and DA D3 receptors in modulating behavioural
impulsivity is largely unknown. In a recent study, infusions
of the DA D3 receptor preferring antagonist nafadotride in
the shell subregion of the nucleus accumbens (NAcb)
further exacerbated impulsive behaviour in high impulsive
(HI) rats. In contrast, infusions of the same compound in
the core subregion of the NAcb reduced impulsivity
(Besson et al. 2010). Since DA D3 receptors are present
in low abundance in the NAcb core relative to the shell
(Booze and Wallace 1995; Curran and Watson 1995), these
findings suggest separable roles of DA D2 and D3
receptors in the control of impulsivity. To test this
possibility, we investigated the effects of the selective DA
D2 receptor agonist sumanirole (McCall et al. 2005)o n
impulsive responding in rats selected on the 5CSRTT. We
hypothesized that HI rats would respond differentially to
sumanirole if DA D2 receptors were selectively down-
regulated in these animals. For comparison, we also tested
the effects of the DA D2/3 receptor agonist quinpirole in
rats selected for extreme impulsivity phenotypes (HI and
low impulsive ‘LI’) on the 5CSRTT, as well as methylphe-
nidate and the selective DAT inhibitor GBR 12909
(Heikkila and Manzino 1984).
Interest has also focused on the brain noradrenergic system
as a potential target for the treatment of ADHD (Biederman
and Spencer 1999). Atomoxetine is the first non-stimulant-
based medication with proven efficacy in ADHD (Caballero
and Nahata 2003; Kratochvil et al. 2002), which acts by
blocking the uptake of NA in the brain (Bymaster et al.
2002), thereby facilitating noradrenergic modulation of
limbic cortico-striatal circuitry (Chamberlain et al. 2007).
Atomoxetine has been shown to be effective in reducing
impulsivity in rats on the 5CSRTT (Blondeau and Dellu-
Hagedorn 2007), delay discounting impulsivity, and impul-
sive behaviour on a stop-signal reaction time task (Robinson
et al. 2009). Although the primary mechanism of action of
atomoxetine is well understood, the downstream effects of
increased synaptic NA function are poorly characterised.
These effects may involve postsynaptic α2-adrenoceptors as
guanfacine, a selective α2-adrenoceptor agonist, possesses
clinical efficacy in ADHD (Scahill et al. 2001) and improves
response inhibition in rodents (Franowicz et al. 2002). In
the present study, therefore, we compared the effects of
atomoxetine and guanfacine in LI and HI rats, specifically
to investigate whether these compounds produce quantita-
tively similar effects on spontaneously high levels of
impulsivity in rats.
Methods and materials
Subjects
Subjects were three cohorts of male Lister hooded rats
(Charles River, Margate, UK) weighing 275–300 g at the
start of each experiment and maintained at 85% of their
free-feeding weight. Subjects were housed initially in
groups of four with controlled temperature and humidity
conditions under an alternating light/dark cycle (red lights
on from 7.30 a.m. to 7.30 p.m.) and with water available ad
libitum. The first cohort of rats (eight HI, seven LI) was
treated with methylphenidate, atomoxetine and guanfacine,
in that order, and each following a washout period of
1 week. The second cohort was treated with quinpirole
(eight HI, eight LI), whilst the third cohort (seven HI, seven
LI) was treated with sumanirole and GBR 12909 (again
separated by a 1-week washout period). Three rats were
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cohorts and one HI rat from the first cohort) due to unstable
performance on the 5CSRTT prior to the drug challenges.
Behavioural training
Subjects were trained to detect the spatial location of a brief
light stimulus presented in one of five open apertures and to
refrain from responding at inappropriate times, as described
previously (Bari et al. 2008). A correct response was
rewarded with the delivery of a single 45-mg sucrose pellet
in the rear magazine (Noyes dustless pellets, 45 mg;
Sandown Scientific, UK). An incorrect nose poke response
in a non-illuminated aperture or a failure to respond within
the set time period resulted in no reward delivery and a
timeout period of 5 s that was occasioned by the house light
being extinguished. A premature response, taken as a
measure of impulsivity (Robbins 2002), was recorded for
responses made in any aperture before the visual cue light
had been presented; again, this led to a 5-s timeout period.
Subjects were trained to a level of at least 80% accuracy
with an intertrial interval (ITI) of 5 s, stimulus duration
(SD) of 0.5 s and a limited hold period of 5 s to make a
response. Each cohort of rats then underwent a screening
procedure to select rats exhibiting extreme impulsivity
phenotypes (LI and HI). During these sessions the ITI was
extended to 7 s to promote the occurrence of a premature
response (see Dalley et al. 2007). The long ITI (LITI)
session consisted of 100 trials and was followed by two
baseline days (ITI 5 s, SD 0.5 s) and two further days where
rats remained in their home cage. This schedule was
repeated three times at weekly intervals. The number of
premature responses for each LITI session was averaged
and ranked. Rats were designated high or low impulsive
rats based on the criteria of premature responses greater
than or equal to 50 premature for all three LITI sessions
(‘HI’) or premature responses less than or equal to 30 for
all LITI sessions (‘LI’), as adopted previously (Dalley et
al. 2007). Rats were then individually housed and
stabilised on the 5CSRTT for five consecutive days prior
to drug testing.
Drugs
(R)-Quinpirole, guanfacine hydrochloride and methylphe-
nidate hydrochloride were commercially sourced (Sigma
Aldrich, UK) and dissolved in 0.9% saline. Atomoxetine
hydrochloride was a generous gift from Eli Lilly Inc. and
was dissolved in 0.01 M phosphate-buffered saline.
Sumanirole ((R)-5,6-dihydro-5-(methylamino)-4H-imidazo
[4,5,1-ij]quinolin-2(1H)-one (Z)-2-butenedioate) was syn-
thesized by Mu-Fa Zou in the Medicinal Chemistry
Section, NIDA-IRP, NIH, Baltimore, USA, using the
published synthesis (Romero et al. 1997) and was dissolved
in 0.01 M phosphate-buffered saline. GBR 12909 dihydro-
chloride was purchased from Sigma (Germany) and
dissolved in distilled deionised water.
Behavioural testing
Drugs were injected in a volume of 1 ml/kg using a Latin
square design. Methylphenidate, atomoxetine, guanfacine
and GBR 12909 were administered intraperitoneally,
20 min before behavioural testing on the 5CSRTT.
Quinpirole and sumanirole were injected subcutaneously
90 and 15 min, respectively, before behavioural testing. Test
sessions consisted of 100 trials, an SD of 0.5 s and an ITI of
5 s and were generally 25 min in duration.
Data analysis
Behavioural data were subjected to a repeated measures
analysis of variance (ANOVA) using the SPSS statistical
package (v19). Significant departures from sphericity
were adjusted using a Greenhouse–Geisser correction of
degrees of freedom to provide more conservative
probabilities. Significant main effects and interactions
were further analysed using ANOVA and SIDAK-
corrected pairwise comparisons. A significance level of
p<0.05 was used for all analyses. Data are presented as
means±SEM.
Results
Quinpirole
Quinpirole produced a significant decrease in premature
responding on the 5CSRTT (dose—F(1.903, 24.736)=15.237,
p<0.001; Fig. 1a). Planned post hoc tests revealed that
premature responding was significantly reduced relative
to the vehicle condition following the administration of
0.01, 0.03 and 0.1 mg/kg for both LI and HI rats.
Quinpirole also significantly increased the number of omis-
sions (dose—F(4, 52)=33.132, p<0.001; Fig. 1b). This effect
was differentially expressed in HI and LI rats (group × dose
interaction—F(4, 52)=3.0, p<0.027) with omissions signifi-
cantly lower in HI rats following a dose of 0.03 mg/kg (p<
0.001). Omissions significantly increased relative to the
vehicle condition following the highest dose of quinpirole in
HI rats and following 0.03 and 0.1 mg/kg in LI rats (all p<
0.005). In addition, quinpirole significantly increased mag-
azine collection latencies (dose—F(4, 52)=46.03, p<0.001;
Fig. 3a) and correct response latencies (dose—F(4, 52)=
3.755, p<0.01; Fig. 3b) but had no significant effect on
attentional accuracy (Fig. 3c).
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Sumanirole significantly reduced premature responding on
the 5CSRTT (dose—F(3, 33)=16.14, p<0.001; Fig. 1c), an
effect that was dependent on baseline levels of impulsivity
(group × dose interaction—F(3, 33)=5.102, p=0.005). Thus,
unlike LI rats, premature responses were significantly reduced
relative to the vehicle condition following all doses of
sumanirole tested in HI rats (0.1 mg/kg, p<0.05;
0.3 mg/kg, p<0.005; 1.0 mg/kg, p<0.001). Premature
responses were significantly higher in HI rats compared
with LI rats for all but the highest dose of sumanirole
evaluated. Omissions also significantly increased follow-
ing the administration of sumanirole (dose—F(3, 33)=
6.123, p<0.005; Fig. 1d); however, this effect was less
marked than in rats treated with quinpirole (compare
Fig. 1 a–f Effects of the DA
D2/D3R agonist quinpirole, the
DA D2R agonist sumanirole and
the selective DA reuptake
inhibitor GBR 12909 on the
number of premature responses
and number of omissions made
by high and low impulsive rats
on the five-choice serial reaction
time task. There were significant
main effects of quinpirole and
sumanirole on premature
responses and omissions
(quinpirole: premature responses
F(1.903, 24.736)=15.237, p<0.001;
omissions F(4, 52)=33.132,
p<0.001; sumanirole: premature
responses F(3, 33)=16.14, p<
0.001; omissions F(3, 33)=6.123,
p<0.005) and a significant main
effect of GBR 12909 on prema-
ture responding [F(2.250, 27.00)=
3.618, p<0.05].*p<0.05, pair-
wise comparisons of mean
responding (vehicle vs dose)
independent of impulsivity phe-
notype. #p<0.05, pairwise com-
parisons of mean responding
(vehicle vs dose, in high impul-
sive rats). Data are means±SEM
344 Psychopharmacology (2012) 219:341–352Fig. 1b). In addition, sumanirole increased magazine
collection latencies (F(1.213, 13.342)=4.839, p<0.05; Fig. 3d)
and correct response latencies (F(1.69, 18.595)=22.056, p<
0.001; Fig. 3e) and like quiniprole had no significant effect
on accuracy (Fig. 3f).
GBR-12909
The effects of the selective DAT inhibitor GBR 12909 on
behavioural performance on the 5CSRTT are shown in
Figs. 1 and 3. GBR 12909 significantly increased prema-
ture responding (dose—F(2.250, 27.00)=3.618, p<0.05;
Fig. 1e), an effect that did not significantly interact with
baseline levels of impulsivity, although there was a
tendency for this compound to reduce impulsivity in HI
rats at the lowest dose tested. No other behavioural
measures were significantly affected by GBR 12909,
including omissions, response latencies and accuracy.
Atomoxetine
Atomoxetine produced a significant reduction in premature
responding (dose—F(4, 52)=5.312, p=0.001; group ×
dose [F(4, 52)=2.539p=0.051]; Fig. 2a), and a significant
increase in the number of omissions [F(2.290, 29.766)=
6.375, p<0.005; Fig. 2b]. These effects were inseparable
with doses of atomoxetine affecting premature respond-
ing in HI rats also significantly increasing omissions
(i.e., 1 and 3 mg/kg). Atomoxetine also significantly
slowed food collection latencies (F(4, 52)=6.069, p<
0.001; Fig. 4b) but had no significant effect on correct
response latencies (Fig. 4a) and attentional accuracy
(Fig. 4c).
Guanfacine
Premature responding on the 5CSRTT was also significantly
reduced by the alpha-2 adrenoceptor agonist guanfacine
(dose—F(4, 48)=5.297, p=0.001; Fig. 2c). This was
significant (vs the vehicle control condition) for HI and LI
rats at the two highest doses of guanfacine tested (0.3 and
1 mg/kg). Guanfacine also significantly increased the
number of omissions (dose—F(1.822, 21.865)=4.170, p<
0.05; Fig. 2d) and correct response latencies (dose:
F(1.445, 17.345)=7.472, p<0.01, Fig. 4e), which reached
statistical significance at the highest dose tested for both
HI and LI groups combined (vehicle vs. 1 mg/kg, p<
0.05). Unlike the other compounds evaluated in this
study guanfacine also significantly affected attentional
accuracy (dose F(1.937, 23.249)=5.812, p<0.01; Fig. 4f)
with the highest dose (1 mg/kg) significantly reducing
accuracy in LI and HI rats relative to the vehicle control
condition.
Methylphenidate
Methylphenidate had no significant effect on premature
responding (Fig. 3e) or other behavioural measures on the
5CSRTT, including omissions (Fig. 3f), magazine collection
latency (Fig. 4g), correct response latency (Fig. 4h)a n d
attentional accuracy (Fig. 4i). However, there was a clear
tendency of this compound to increase premature respond-
ing in both the LI and HI groups despite the evidently large
inter-individual variation in responsiveness of HI rats,
especially at the highest dose tested.
Discussion
The main findings of this study demonstrate divergent
functional roles of the dopaminergic and noradrenergic
systems in the modulation of impulsive behaviour and
attentional performance in rats and provide additional
support for the notion that DA receptor dysfunction
associates with extreme impulsivity endophenotypes on
the 5CSRTT. Selective inhibition of the NA and DA
transporters by atomoxetine and GBR 12909, respectively,
decreased and increased impulsive behaviour on the
5CSRTT, whereas methylphenidate, a compound used
widely to treat ADHD, was without significant effect.
Activation of DA D2-like receptors by the D2/3 receptor
agonist quinpirole and the selective D2 receptor agonist
sumanirole resulted in a dose-dependent decrease in
impulsivity that, at lower doses (0.01 mg/kg quinpirole
and 0.1 mg/kg sumanirole), was selectively mediated and
devoid of effects on attentional accuracy as well as the
speed and rate of responding (Table 1). Higher doses of
quinpirole and sumanirole resulted in more general effects
on performance and behavioural output. However, these
non-specific effects differed between HI and LI rats with
sumanirole producing less pronounced effects on omissions
(a gross measure of inattention) than quinpirole. Moreover,
the slowing of responding produced by higher doses of
quinpirole and the concomitant rise in omissions was
blunted in high impulsive rats compared with low impul-
sive rats. By contrast, the selective alpha-2 adrenoceptor
agonist, guanfacine, produced qualitatively and quantita-
tively similar effects on behavioural performance in rats
selected for high and low impulsivity compared with
atomoxetine. Taken together, the present results indicate
that high impulsivity in rats can be remediated by direct and
indirect NA and DA agonists. These effects appear
dissociable from the potential confounding influence of
behavioural activation mechanisms, specifically following
low doses of quinpirole and sumanirole.
Previous research has established that high impulsivity
of rats on the 5CSRTT predicts the escalation of cocaine,
Psychopharmacology (2012) 219:341–352 345nicotine and sucrose self-administration (Dalley et al. 2007;
Diergaarde et al. 2008, 2009), and also a tendency towards
compulsive cocaine seeking and to relapse (Belin et al.
2008; Economidou et al. 2009). High impulsive rats also
show reduced DA D2/3 receptor binding in the ventral
striatum, including the NAcb, but not the dorsal striatum
(Dalley et al. 2007) and reduced dopamine release in the
nucleus accumbens core (Diergaarde et al. 2008). High
impulsivity is remediated by the DA D2/3 receptor
antagonist nafadotride infused in the nucleus accumbens
core but exacerbated by infusions of the same compound in
the shell subregion (Besson et al. 2010). This evidence
together with findings that DA D2 receptor antagonism in
the nucleus accumbens core reduces impulsivity produced
by systemic amphetamine as well as selective PFC lesions
(Pattij et al. 2007;P e z z ee ta l .2009) highlights an
important role of DA-ergic inputs to the nucleus accumbens
core in regulating impulsive-like behaviour.
Similar to recently reported effects of full and partial
D2/3 receptor agonists in selected impulsive rats (Besson et
Fig. 2 a–f Effects of the NA
reuptake inhibitor atomoxetine,
the α2-adrenoreceptor agonist,
guanfacine and the nonselective
DA and NA reuptake inhibitor
methylphenidate on premature
responses and omissions on the
five-choice serial reaction time
task. There were significant
main effects of atomoxetine and
guanfacine on premature
responding and omissions
(atomoxetine: premature
responses F(4, 52)=5.312, p=
0.001; omissions F(2.290, 29.766)=
6.375, p<0.005; guanfacine:
premature responses F(4, 48)=
5.297, p=0.001; omissions
F(1.822, 21.865)=4.170, p<0.05).
*p<0.05, pairwise comparisons
of mean responding (vehicle vs
dose) independent of impulsivi-
ty phenotype. Data are means±
SEM
346 Psychopharmacology (2012) 219:341–352al. 2010; Winstanley et al. 2010), systemic administration
of sumanirole and quinpirole resulted in a dose-dependent
reduction in impulsivity. Although floor effects in the low
impulsive group may have had a bearing on these results,
low doses of sumanirole were effective in selectively
reducing premature responding in high impulsive rats.
Sumanirole is a highly selective D2 receptor agonist
possessing a 200-fold greater affinity for D2 than D1, D3
and D4 receptors (McCall et al. 2005) and thus may be a
useful compound to determine whether D2 rather than D3
receptors are selectively disrupted in high impulsive rats.
Our results show that sumanirole and quinpirole produce a
broadly equivalent profile of effects on impulsivity, omis-
sions and speed of responding with one exception; high
impulsives were less sensitive to the effects of quinpirole on
omissions. The origin of this possible divergent response is
Fig. 3 a–i Effects of quinpirole, sumanirole and GBR-12909 on food
collection latencies, correct response latencies and attentional
accuracy on the five-choice serial reaction time task. There were
significant main effects of quinpirole and sumanirole on food
collection latencies and correct response latencies (quinpirole:
magazine latencies F(4, 52)=46.03, p<0.001; correct response
latencies F(4, 52)=3.755, p<0.01; sumanirole: magazine latencies
F(1.213,13.342)=4.839, p<0.05; correct response F(1.69, 18.595)=22.056,
p<0.001). *p<0.05, pairwise comparisons of mean responding
(vehicle vs dose). Data are means±SEM
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treated with higher doses of sumanirole. Previous research
indicates that the direct administration of quinpirole in the
nucleus accumbens core, an area with a low abundance of
D3 receptors (Bouthenet et al. 1991), does not increase
omissions even after relatively high doses (Pezze et al.
2009). Indeed, microinfusions of the D2 receptor antagonist
eticlopride in the core leads to a significant increase in
omissions on the 5CSRTT (Pattij et al. 2007). Moreover,
although quinpirole likewise increased omissions on this
task when infused in the orbitofrontal cortex (OFC), this
effect was no different between low and high impulsive rats
(Winstanley et al. 2010). Thus, the differential increase in
omissions induced by quinpirole in HI and LI rats appears
to be mediated by structures other than the nucleus
accumbens core and OFC.
Fig. 4 a–i Effects of atomoxetine, guanfacine and methylphenidate
on food collection latencies, correct response latencies and attentional
accuracy on the five-choice serial reaction time task. There was a
significant main effect of atomoxetine on food collection latencies
(F(4, 52)=6.069, p<0.001) and significant main effects of guanfacine
on correct response latencies (F(1.445, 17.345)=7.472, p<0.01) and
attentional accuracy (F(1.937, 23.249)=5.812, p<0.01). *p<0.05, pair-
wise comparisons of mean responding (vehicle vs dose). Data are
means±SEM
348 Psychopharmacology (2012) 219:341–352The neural loci underlying the reduction in impulsive
behaviour following quinpirole and sumanirole administra-
tion remain to be clarified but putatively may involve the
PFC (including the OFC), nucleus accumbens and DA
neurons in the ventral tegmental area (Dalley et al. 2011). In
a recent study, intra-OFC quinpirole administration in low
and high impulsive rats produced a generalized disruption
in performance on the 5CSRTT with effects on premature
responding, accuracy, omissions and response latencies
(Winstanley et al. 2010). Such effects suggest that D2/3
receptors in this region do not play a selective role in
impulse control. The disruptive effects of intra-OFC
quinpirole in this setting could potentially be mediated
through effects on postsynaptic D2/3 receptors since
mesocortical DA neurons are deficient in (or lack)
presynaptic autoreceptors (Bannon et al. 1982;C h i o d oe t
al. 1984). However, the same is not true of mesolimbic DA
neurons innervating the nucleus accumbens, which are
subject to regulation by D2/3 autoreceptors (Benoit-Marand
et al. 2001; Schmitz et al. 2002). Thus, the decrease in
impulsivity caused by low-dose quinpirole and sumanirole
may be due, in part, to diminished DA release in the
nucleus accumbens, leading in turn to a reduction in
behavioural activation (Robbins and Everitt 2007). A
plausible candidate for this effect is the postsynaptic D1
receptor as blockade of these receptors in the core, but not
the shell, of the nucleus accumbens reduced impulsivity on
the 5CSRTT (Pattij et al. 2007), whereas administration of
the D1 receptor agonist SKF 38393 in the core had the
opposite effect (Pezze et al. 2007).
Systemic administration of atomoxetine, a selective NA
reuptake inhibitor (Bymaster et al. 2002), and guanfacine, a
selective alpha-2 adrenoceptor agonist (Arnsten et al.
2007), resulted in a dose-dependent decrease in impulsivity
but at doses which also increased omissions and adversely
affected the speed of responding. Such non-specific effects
are consistent with reports of sedation in animal studies
(Milstein et al. 2010) and clinical subgroups treated with
guanfacine (Biederman et al. 2004). At higher doses,
atomoxetine also appeared to exhibit sedative effects as
reflected by increased response latencies, omissions as well
as reduced general activity (present study and see Blondeau
and Dellu-Hagedorn 2007). However, lower doses have
been shown to selectively reduce impulsivity on a broad
Table 1 Summary of the main behavioural effects of direct and indirect noradrenergic and dopaminergic agonists on the behavioural performance
of rats on the five-choice serial reaction time task
↑ Increase with respect to vehicle, ↓ with respect to vehicle, − no change with respect to vehicle. Note that the effects on premature responding for
quinpirole and sumanirole occur at doses with no effects on response latencies or omissions.
Psychopharmacology (2012) 219:341–352 349range of tasks, including the 5CSRTT (Blondeau and Dellu-
Hagedorn 2007; Robbins and Everitt 2007; Navarra et al.
2008), stop-signal reaction time task and the delay
discounting paradigm (Robinson et al. 2008). The lack of
selective effects of atomoxetine in the present study may be
due to the inclusion of high impulsive rats, which exhibited
a more pronounced response than low impulsive rats (in
terms of omissions and response latencies) to a moderate
dose of atomoxetine (1 mg/kg). Atomoxetine and guanfa-
cine are postulated to facilitate PFC function and improve
sustained attention by indirectly or directly stimulating
postsynaptic alpha-2 adrenoceptors (Arnsten et al. 2007;
Sagvolden 2006; Bymaster et al. 2002) reflected in the
similar behavioural effects of these compounds in the
present study.
The primary effects of methylphenidate in the brain are
to increase NA and DA neurotransmission by blocking the
NA and DA transporters (Elia et al. 1999; Kutcher et al.
2004; Solanto 2002; McKittrick and Abercrombie 2007).
Consistent with earlier findings (van Gaalen et al. 2006),
selective blockade of the DA transporter by GBR 12909 in
the present study resulted in a significant increase in
premature responding. Based on previous evidence, this
effect was most likely mediated by the activation of D1 and
D2 receptors in the nucleus accumbens, in particular within
its core subregion. Thus, in addition to the prominent role
for D1 receptors in impulsivity (see above), D2 receptors
also powerfully modulate the effects of stimulant drugs
such as d-amphetamine on impulse control (van Gaalen et
al. 2006). This interaction has recently been localised to the
nucleus accumbens core as demonstrated by the complete
blockade of d-amphetamine-induced impulsivity on the
5CSRTT by intra-core infusions of the D2 receptor
antagonist eticlopride (Pattij et al. 2007). Moreover, the
D2 receptor antagonist sulpiride strongly attenuates the
elevation in premature responding induced by PFC lesions
when directly administered in the nucleus accumbens core
(Pezze et al. 2009).
In the present study, methylphenidate did not significantly
affect premature responding in high and low impulsive rats.
Previous studies report increased impulsivity in rats treated
with methylphenidate when tested with the usual constant ITI
in the 5CSRTT (Milstein et al. 2010; Navarra et al. 2008;
Blondeau and Dellu-Hagedorn 2007), and our present
findings indicate that this was indeed the case for low
impulsive rats with a near doubling in the frequency of
premature responses following the administration of meth-
ylphenidate. In the less common variant of the task when
premature responses are recorded but not punished, methyl-
phenidate has the opposite effect and reduces impulsivity
(Bizarro et al. 2004). Earlier evidence also indicates that
low-dose methylphenidate improves visual attention and
lowers impulsivity in rats selected for poor baseline
performance on the 5CSRTT (Puumala et al. 1996). Thus,
the effects of methylphenidate on impulse control are
evidently dependent on baseline levels of impulsivity,
consistent with the rate-dependent effects of this compound
in children (Robbins and Sahakian 1979). Such a relation-
ship seen in this study with methylphenidate suggests at least
two mechanisms, which may not be mutually exclusive.
Firstly, the effects of NA, which functions to inhibit
impulsive responding, may be greater in high impulsive rats
or at least sufficient to cancel out the DA-enhancing effects
of methylphenidate. Secondly, the behavioural activating
effects of DA are blunted in high impulsive rats. This second
mechanism would be compatible with the finding of reduced
D2/3 receptor availability in high impulsive rats (Dalley et
al. 2007) if indeed such effects were localised to the nucleus
accumbens core. Finally it should be noted that we observed
a large inter-individual response to methylphenidate in high
impulsive rats, especially at higher doses. This variation may
reflect differences in the extent of the primary neurochemical
deficit in hyper-impulsive rats in terms of NA and DA
function or polymorphisms of the NA and DA transporter
genes which may underlie variation in the clinical response
to methylphenidate (Roman et al. 2004;Y a n ge ta l .2004).
In conclusion, the main findings of this study indicate
that dopaminergic and noradrenergic mechanisms have
divergent functional roles in the modulation of hyper-
impulsivity in rats on the five-choice serial reaction time
task. In contrast to the direct and indirect NA receptor
agonists guanfacine and atomoxetine, the selective D2/3
receptor agonists sumanirole and quinpirole attenuated
impulsivity on this task at doses that did not produce
excessive sedation. The differential effects of quinpirole in
high impulsive rats are consistent with D2/3 receptor
dysfunction in this subset of animals, which may have
relevance for the elucidation of neural vulnerability
mechanisms underlying stimulant addiction.
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